Breastfeeding is known to reduce risks of breast cancer, ovarian cancer and type 2 diabetes and this study suggests that breastfeeding is associated with lower risk of heart disease.
TITLE
Breastfeeding Is Associated With a Reduced Maternal Cardiovascular Risk: Systematic Review and Meta-Analysis Involving Data From 8 Studies and 1 192 700 Parous Women.
JOURNAL
Journal of the American Heart Association
DOI
10.1161/JAHA.121.022746
Author(s)
L Tschiderer;L Seekircher;SK Kunutsor;SAE Peters;LM O'Keeffe;P Willeit
Abstract
Background: Breastfeeding has been robustly linked to reduced maternal risk of breast cancer, ovarian cancer, and type 2 diabetes. A progressive risk reduction of all CVD outcomes with lifetime durations of breastfeeding from 0 up to 12 months was found, with some uncertainty about shapes of associations for longer durations. Conclusions Breastfeeding was associated with reduced maternal risk of CVD outcomes.
https://www.focalize.md/find-journals/?a=y0auU34BEtb5a2zzs7VV
Newer diabetic medications that stimulate release of insulin from the pancreas are used for type 2 diabetics. Now they are being studied for treatment of obesity and this study shows weight loss sustained at 68 weeks - more than a year.
TITLE
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JOURNAL
JAMA
DOI
10.1001/jama.2021.23619
Author(s)
DM Rubino;FL Greenway;U Khalid;PM O'Neil;J Rosenstock;R Sørrig;TA Wadden;A Wizert;WT Garvey;
Abstract
Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management. Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide. Conclusions and Relevance: Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss at 68 weeks. Trial Registration ClinicalTrials.gov Identifier: NCT04074161.
https://www.focalize.md/find-journals/?a=gkauU34BEtb5a2zzs7ZV
